Protheragen Obesity



Bay 11-7085

Cat. No.:	OB0225WX-2682
Appearance:	Solid
Purity:	≥99%
Identity:	Confirmed by NMR, and HPLC.
Size:	10 mg; 25 mg; 50 mg; 100 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	BAY 11-7085 is an irreversible antagonist of TNF-alpha-induced I-kappa-B-alpha p hosphorylation, characterized by a half-maximal inhibitory concentration (IC50) of 10 micromolar.
Synonym	bay 11-7085; 196309-76-9; (*E*)-3-((4-(tert-Butyl)phenyl)sulfonyl)acrylonit rile; (*E*)-3-(4-tert-butylphenylsulfonyl)acrylonitrile; bay11-7085; BAY 11 -7083; (*E*)-3-(4-tert-butylphenyl)sulfonylprop-2-enenitrile; MFCD01862602; BAY-117085; (*E*)-3-(4-t-Butylphenylsulfonyl)-2-propenenitrile; BAY-11-708 5; (2*E*)-3-[[4-(1,1-Dimethylethyl)phenyl]sulfonyl]-2-propenenitrile; 3-((4 -(1,1-dimethylethyl)phenyl)sulfonyl)-2-propenenitrile; BAY 11-7085; (*E*)-3 -[[4-(1,1-Dimethylethyl)phenyl]sulfonyl]-2-propenenitrile; BAY 117083; BAY 11708 5; 2-Propenenitrile, 3-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-, (2*E*)-; (*E*)-3-(4-tert-Butyl-benzenesulfonyl)-acrylonitrile; (*E*)-3-(4-tert-b utylphenyl)sulfonyl-2-propenenitrile; (*E*)-3-(4-tert-butylphenylsulfonyl)- 2-propenenitrile; (2*E*)-3-[(4-tert-butylphenyl)sulfonyl]prop-2-enenitrile; (2*E*)-3-(4-tert-butylbenzene-1-sulfonyl)prop-2-enenitrile
CAS No.	196309-76-9
Compound CID	5353432
Formula	$C_{13}H_{15}NO_2S$
Formula Weight	249.33

Specification

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com

Protheragen Obesity



IUPAC Name	(*E*)-3-(4-*tert*-Butylphenyl)sulfonylprop-2-enenitrile
InChI	InChI=1S/C13H15NO2S/c1-13(2,3)11-5-7-12(8-6-11)17(15,16)10-4-9-14/h4-8,10H,1-3H3/b10-4+
InChI Key	VHKZGNPOHPFPER-ONNFQVAWSA-N
SMILES string	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Bay 11-7085 is applied in molecular biology research to study the irreversible i nhibition of IkappaB-alpha phosphorylation and its subsequent impact on preventi ng NF-kappaB-mediated pro-inflammatory gene expression.

Library Information

Target	IκB/IKK
Receptor	IκBα
Pathways	NF-κB
Plate Number	L6700-08
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	50 mg/mL; 200.54 mM
Ethanol Max Solubility	50 mg/mL
ALogP	2.635
HBA_Count	2
HBD_Count	0
Rotatable Bond	3

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com